When was LeadInvent founded?

LeadInvent was founded in 2006.

Where is LeadInvent located?

LeadInvent is headquartered in Exton, United States. It is registered at BIOTECH CENTRE, 2 ND FLOOR,UNIVERSITY OF DELHI SOUTH CAMPUS,BENITO JUAREZ ROAD, NEW DELHI, Delhi, India, 110021.

Who is the current CEO of LeadInvent?

Pankaj Sharma of LeadInvent. They are also angel investors in 11 startups, including .

Which legal entities is LeadInvent associated with?

LeadInvent is associated with LEADINVENT TECHNOLOGIES PRIVATE LIMITED.

How many employees does LeadInvent have?

As of Apr 30, 2026, the latest employee count at LeadInvent is 3.

Is LeadInvent a funded company?

LeadInvent is a funded company, having raised a total of $***** in its 1st and only funding round.

What is the annual revenue of LeadInvent?

Annual revenue of LeadInvent is less than ₹10 Cr as on Mar 31, 2020

Where does LeadInvent rank among its competitors?

LeadInvent ranks 701st amongst 696 active competitors, of which 231 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of LeadInvent?

LeadInvent's top competitors include Alnylam, Spark Therapeutics and Strand Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

LeadInvent - 2026 Company Profile, Team, Funding, Competitors & Financials

LeadInvent is a deadpooled company based in Exton (United States), founded in 2006 by Pankaj Sharma and Surojit Bose. It operates as a Molecule simulation technology for drug discovery & computer-aided drug design for small molecules.. The company has 696 active competitors, including 231 funded and 143 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Strand Therapeutics.

Company Details

LeadInvent has developed unique molecule simulation platform (christened LIDiscoverEngine). This simulation platform enables scientist to design and study molecules virtually on supercomputing platform before such molecules are synthesized and tested experimentally. The computational platform can be be used for - accurately predicting molecule binding; calculating binding energies between ligand and protein; unraveling protein conformations by going beyond crystal 3D structures; understanding bound vs. unbound states of molecules; predicting activity of a molecule across 8000 library targets; screening an 8 million compound library; and building a molecule inside the protein cavity using small molecule fragments. LIDiscoverEngine has been successfully used in over five drug discovery programs spanning Oncology, Infectious diseases and CNS indications. LeadInvent has been awarded with multiple grants from the Government of India including SBIRI, BIPP and CRS programs.

Website: leadinvent.com
Social
Registered Address: BIOTECH CENTRE, 2 ND FLOOR,UNIVERSITY OF DELHI SOUTH CAMPUS,BENITO JUAREZ ROAD, NEW DELHI, Delhi, India, 110021

Key Metrics

Founded Year

2006

Location

Exton, United States

Stage

Deadpooled

Investors

Department of Biotechnology & 1 more

Ranked

701^st among 899 competitors

Annual Revenue

0 - ₹10 Cr as on Mar 31, 2020

Employee Count

3 as on Apr 30, 2026

Similar Companies

Alnylam & 897 more

View LeadInvent's full profile

LeadInvent is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LEADINVENT TECHNOLOGIES PRIVATE LIMITED CIN: U72900DL2006PTC155445 , India, Active	Nov 14, 2006	0 - ₹10 Cr (As on Mar 31, 2020)	-

LeadInvent is a funded company. LeadInvent has 2 institutional investors.

View details of LeadInvent's funding rounds and investors

The founders of LeadInvent are Pankaj Sharma and Surojit Bose.

Here are the details of LeadInvent's key team members:

Pankaj Sharma: Founder & CEO of LeadInvent. They are also an angel investor in 11 startups and serve on the boards of 2 companies.
Contact Info: 2 email addresses
Surojit Bose: Co-Founder of LeadInvent and founder of 1 other company. They are also an angel investor in 3 startups and serve on the board of 1 company.
Contact Info: 1 email address and 1 phone number

LeadInvent's Board of Directors

LeadInvent's board has 3 active members. Pankaj Sharma and Surojit Bose are part of team and Praveen Agrawal is independent board member.

Here is the list of LeadInvent's board of directors:

Name	Type	Representing	Status	Duration
Pankaj Sharma	Team	-	Current	19y 7m
Surojit Bose	Team	-	Current	19y 3m
Praveen Agrawal	Independent board member	-	Current	19y 7m

View details of LeadInvent's Founder profiles and Board Members

LeadInvent's employee count trend

LeadInvent has 3 employees as of Apr 26. Here is LeadInvent's employee count trend over the years:

Uncover LeadInvent's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LeadInvent include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of LeadInvent, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, Xontogeny & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Adage Capital Management, F-Prime Capital ... & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Danforth Advisors, Frazier Life Sciences & 2 others	67/100
701st	LeadInvent 2006, Exton (United States), Deadpooled	Molecule simulation technology for drug discovery & computer-aided drug design for small molecules.	-	Department of Biotechnology, BIRAC	19/100